ValiRx - Successful Evaluation of Triple Negative Breast Cancer Programme
VAL Thu, 14 Jul 2022, 01:30pm BST
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Industry: Health Care
Contact: +44 (0)2476 796496
Dr. Suzy Dilly, CEO of ValiRx, discusses the successful evaluation of the company's triple negative breast cancer programme.